OMEROS CORP Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit
OMEROS CORP (OMER) had Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit of $0 as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit · last filed 2025-03-31
- 2024-12-31: Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $0.00.
| Period end | Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |